A review of NMDA receptors and the phencyclidine model of schizophrenia

Sheri A. Thornberg; Stephen R. Saklad

A review of NMDA receptors and the phencyclidine model of schizophrenia

Sheri A. Thornberg, Stephen R. Saklad

Research output: Contribution to journal › Review article › peer-review

Abstract

Current models of drug-induced psychosis insufficiently describe the symptoms of schizophrenia. Phencyclidine-induced psychosis is a model that more completely reflects the pathophysiology of the disease. By decreasing glutamatergic neurotransmission, phencyclidine decreases γ-aminobutyric acid release from the nucleus accumbens, striatum, and hippocampus (manifested by MK-801); may inhibit tonic release of dopamine from the nucleus accumbens and striatum, resulting in increased dopamine phasic reactivity; and decreases long-term potentiation. Glutamatergic system dysfunction may be involved, but pharmacologic manipulation has not revealed a clear mechanism of this dysfunction.

Original language	English (US)
Pages (from-to)	82-93
Number of pages	12
Journal	Pharmacotherapy
Volume	16
Issue number	1 I
State	Published - Feb 1 1996

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

Fingerprint Dive into the research topics of 'A review of NMDA receptors and the phencyclidine model of schizophrenia'. Together they form a unique fingerprint.

Cite this

@article{39a5ffa93c5246f98846c29bb4d84630,

title = "A review of NMDA receptors and the phencyclidine model of schizophrenia",

abstract = "Current models of drug-induced psychosis insufficiently describe the symptoms of schizophrenia. Phencyclidine-induced psychosis is a model that more completely reflects the pathophysiology of the disease. By decreasing glutamatergic neurotransmission, phencyclidine decreases γ-aminobutyric acid release from the nucleus accumbens, striatum, and hippocampus (manifested by MK-801); may inhibit tonic release of dopamine from the nucleus accumbens and striatum, resulting in increased dopamine phasic reactivity; and decreases long-term potentiation. Glutamatergic system dysfunction may be involved, but pharmacologic manipulation has not revealed a clear mechanism of this dysfunction.",

author = "Thornberg, {Sheri A.} and Saklad, {Stephen R.}",

year = "1996",

month = feb,

day = "1",

language = "English (US)",

volume = "16",

pages = "82--93",

journal = "Pharmacotherapy",

issn = "0277-0008",

publisher = "Pharmacotherapy Publications Inc.",

number = "1 I",

}

TY - JOUR

T1 - A review of NMDA receptors and the phencyclidine model of schizophrenia

AU - Thornberg, Sheri A.

AU - Saklad, Stephen R.

PY - 1996/2/1

Y1 - 1996/2/1

N2 - Current models of drug-induced psychosis insufficiently describe the symptoms of schizophrenia. Phencyclidine-induced psychosis is a model that more completely reflects the pathophysiology of the disease. By decreasing glutamatergic neurotransmission, phencyclidine decreases γ-aminobutyric acid release from the nucleus accumbens, striatum, and hippocampus (manifested by MK-801); may inhibit tonic release of dopamine from the nucleus accumbens and striatum, resulting in increased dopamine phasic reactivity; and decreases long-term potentiation. Glutamatergic system dysfunction may be involved, but pharmacologic manipulation has not revealed a clear mechanism of this dysfunction.

AB - Current models of drug-induced psychosis insufficiently describe the symptoms of schizophrenia. Phencyclidine-induced psychosis is a model that more completely reflects the pathophysiology of the disease. By decreasing glutamatergic neurotransmission, phencyclidine decreases γ-aminobutyric acid release from the nucleus accumbens, striatum, and hippocampus (manifested by MK-801); may inhibit tonic release of dopamine from the nucleus accumbens and striatum, resulting in increased dopamine phasic reactivity; and decreases long-term potentiation. Glutamatergic system dysfunction may be involved, but pharmacologic manipulation has not revealed a clear mechanism of this dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0030041171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030041171&partnerID=8YFLogxK

M3 - Review article

C2 - 8700797

AN - SCOPUS:0030041171

VL - 16

SP - 82

EP - 93

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1 I

ER -